Christopher Sibley

Christopher Sibley is a seasoned medical professional with extensive experience in clinical development and research, particularly in cardiology and atherosclerosis. Currently serving as the Global Clinical Development Lead for Palopegteriparatide at Ascendis Pharma since November 2020, Christopher previously held roles such as Medical Director at Great Point Health and Clinical Director at Merck. Christopher's academic credentials include an A.B. in Philosophy of Science from Princeton University and a Doctor of Medicine from Northwestern University. Notable past positions include Assistant Professor of Cardiology at Knight Cardiovascular Institute, Staff Clinician at the National Institutes of Health, and Chief Medical Resident at Northwestern Memorial Hospital. Christopher's work has involved leading clinical studies focusing on cardiovascular diseases, heart failure, and advanced imaging techniques.